



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 15th February, 2018

**To,
Mr. Hiren Shah,
Manager,
National Stock Exchange of India Limited,
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400051**

**Sub: - Non-Compliance as per Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015**
Ref: NSE/LIST/FR/5066 dated 15.02.2018

Dear Sir,

With reference to the captioned letter regarding Non-Compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to mention that the quick results submitted on 14th February, 2018 were inadvertently submitted without attaching the Limited Review Report.

However, the same has been attached in the full results submitted on 15th February, 2018.

Therefore, kindly consider and take the same on record the Unaudited Financial Results along with the Limited Review Report attached herewith for the quarter ended 31st December, 2017.

**Thanking You
For Parenteral Drugs (India) Limited**

Madhava
Company Secretary



Attached: A/a




PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR TO DATE 31ST DECEMBER, 2017

Particulars	(Rs in Lakh, unless otherwise stated)				
	Quarter Ended 31-12-2017 (Unaudited)	Quarter Ended 30-09-2017 (Unaudited)	Quarter Ended 31-12-2016 (Unaudited)	Year to Date 31-12-2017 (Unaudited)	Year to Date 31-12-2016 (Unaudited)
Refer Notes below			(Ref. note 4 below)		(Ref. note 4 below)
Income					
(a) Revenue From Operation (Gross)	792.84	1,082.17	870.86	2,986.13	4,188.42
(b) Other Operating Income	27.25	26.14	32.08	117.08	39.82
Total Income (I+II)	820.09	1,108.31	902.94	3,103.21	4,228.24
Expenditure					
Cost of Material Consumed	96.17	149.68	145.53	353.30	1,079.84
Purchase of Stock In Trade	(15.81)	38.66	48.85	107.52	563.63
Change in Inventories of Finished Goods, Stock In trade and Work in Progress	176.82	(71.96)	111.46	127.92	323.27
Employee Benefit Expenses	340.72	304.03	483.97	968.82	1,164.64
Finance costs	2,177.27	2,215.27	1,907.99	6,413.96	5,521.62
Depreciation, Amortisation and Impairment Expenses	451.82	452.68	582.48	1,357.18	1,485.68
Other Expenditure	685.41	926.13	720.40	2,468.47	2,509.51
Total Expenses (IV)	3,912.40	4,014.49	4,000.68	11,797.17	12,648.19
Profit / (Loss) before exceptional items and Tax (I-IV)	(3,092.31)	(2,906.18)	(3,097.74)	(8,693.96)	(8,419.95)
Exceptional items	-	-	-	-	-
Profit / (Loss) before Tax (V-VI)	(3,092.31)	(2,906.18)	(3,097.74)	(8,693.96)	(8,419.95)
Tax Expenses					
(1) Current Tax	-	-	-	-	-
(2) Deferred Tax	(624.57)	(635.29)	(442.99)	(1,814.17)	(1,311.11)
Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(2,467.73)	(2,270.89)	(2,654.75)	(6,879.79)	(7,108.84)
Net Profit / (Loss) for the period from discontinuing operations	-	-	-	-	-
Tax expense of discontinuing operations	-	-	-	-	-
Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-	-	-	-
Profit/(loss) for the period (IX+XII)	(2,467.73)	(2,270.89)	(2,654.75)	(6,879.79)	(7,108.84)
Other Comprehensive Income					
A (i) Item that will not be reclassified to Profit or loss	(3.04)	(60.06)	(8.48)	(63.54)	(35.01)
(ii) Income tax relation to Item that will not be reclassified to Profit or loss	-	-	-	-	-
B (i) Item that will be reclassified to Profit or loss	-	-	-	-	-
(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-	-	-	-
Total comprehensive Income for the period (XIII+XIV) (comprising profit (loss) and other comprehensive income for the period)	(2,470.77)	(2,330.95)	(2,663.23)	(6,943.33)	(7,143.85)
Paid Up Equity share capital (Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63
Earnings per share (for continuing operation) :					
(a) Basic (In Rs)	(8.28)	(7.62)	(8.90)	(23.07)	(23.84)
(b) Diluted (In Rs)	(8.28)	(7.62)	(8.90)	(23.07)	(23.84)
Earnings per share (for discontinued operation) :					
(a) Basic (In Rs)	-	-	-	-	-
(b) Diluted (In Rs)	-	-	-	-	-
Earnings per share (for discontinued & continuing operation) :					
(a) Basic (In Rs)	(8.28)	(7.62)	(8.90)	(23.07)	(23.84)
(b) Diluted (In Rs)	(8.28)	(7.62)	(8.90)	(23.07)	(23.84)

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ MS0809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

The above results were reviewed by the audit committee at their meeting and thereafter approved by Board of Directors at their meeting held on 14-02-2018. The statutory auditors of the company have carried out limited review of the aforesaid results. The standalone financial results for the quarter ended December 31, 2017 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017, the Company has for the first time adopted Ind AS with the transition date of April 1, 2016.

The Ind AS compliant corresponding figures for the previous quarter have not been subjected to review. However, the Company's management has exercised due diligence to ensure that such financial results provided a true and fair view of its affairs.

Reconciliation of the net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:-

Description	Quarter ended 31.12.2016 Rs. In lakh	Year to Date 31.12.2016 Rs. In lakh
Net profit as per previous GAAP (Indian GAAP)	(2,576.38)	(6,913.70)
Provisions for receivable on Expected credit loss model	(0.76)	55.50
Fair valuation on account of Preference shares issued	(91.35)	(274.05)
Employee Benefits Expenses	12.21	36.64
Deferred tax impact on above	0.23	(17.15)
Others	1.31	3.93
Net Profit as per Ind AS	(2,654.74)	(7,108.83)
Other comprehensive income (net of tax expenses)	(8.48)	(35.01)
Total comprehensive income	(2,663.22)	(7,143.84)

At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.

The previous period figures have been regrouped/rearranged wherever found necessary.

The Standalone financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Place: Indore
Date: 14th February 2018

Vinod Kumar Gupta
Managing Director
DIN 00039145



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ MS019:2015

JAS-ANZ



www.jas-anz.org/register

Singhal Jain & Co.

Chartered Accountants

Standalone Limited Review Report

Limited Review Report to

The Board of Directors of Parenteral Drugs (India) Limited

We have reviewed the accompanying statement of unaudited financial results of **Parenteral Drugs (India) Limited** for the quarter ended **31st December, 2017** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. IND AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore (MP)

Date: 14/02/2018

For Singhal Jain & Co.

Chartered Accountants

Kamal Jain
CA Kamal Jain
(Partner)



M No. 406604

F.N.N.013995C




PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR TO DATE 31ST DECEMBER, 2017

Sr. No.	Particulars	Quarter Ended 31-12-2017 (Unaudited)	(Rs in Lakh) Quarter Ended 30-09-2017 (Unaudited)	Quarter Ended 31-12-2016 (Unaudited)	Year to Date 31-12-2017 (Unaudited)	Year to Date 31-12-2016 (Unaudited)
				(Ref. note 5 below)		(Ref. note 5 below)
I	(a) Revenue From Operation	5297.45	7358.85	4,626.51	18900.48	18755.16
II	(b) Other Income	36.20	25.20	33.02	132.69	44.99
III	Total Income (I+II)	5333.65	7384.05	4,659.53	19033.17	18800.15
IV	Expenditure					
	Cost of Material Consumed	2345.06	2418.32	2,137.91	7115.09	7845.84
	Purchase of Stock In Trade	1104.50	1508.40	1,037.62	4968.69	4610.77
	Change in Inventories of Finished Goods, Stock In trade and Work in Progress	377.02	732.67	25.53	1285.49	218.81
	Employee Benefit Expenses	482.01	425.38	603.57	1348.37	1553.97
	Finance costs	2434.00	2527.96	2,191.92	7269.76	6402.97
	Depreciation and Amortisation Expenses	600.95	602.40	731.45	1805.76	1932.60
	Other Expenditure	2248.07	2742.48	1,288.06	6775.95	5243.40
	Total Expenses (IV)	9591.61	10957.61	8,016.06	30569.10	27808.36
V	Profit / (Loss) before exceptional items and Tax (I-IV)	(4,257.96)	(3,573.56)	(3,356.53)	(11,535.93)	(9,008.21)
VI	Exceptional Items	-	-	-	-	-
VII	Profit / (Loss) before Tax (V-VI)	(4,257.96)	(3,573.56)	(3,356.53)	(11,535.93)	(9,008.21)
VIII	Tax Expenses	-	-	-	-	-
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	(616.10)	(608.71)	(411.85)	(1752.05)	(1198.61)
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(3,641.85)	(2,964.85)	(2,944.68)	9,783.87	(7,809.60)
X	Net Profit / (Loss) for the period from discontinuing operations	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(3,641.85)	(2,964.85)	(2,944.68)	9,783.87	(7,809.60)
XIV	Other Comprehensive Income					
	A (i) Item that will not be reclassified to Profit or loss	(3.04)	(60.06)	(8.48)	(63.54)	(35.01)
	(ii) Income tax relation to Item that will not be reclassified to	-	-	-	-	-
	B (i) Item that will be reclassified to Profit or loss	-	-	-	-	-
	(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-	-	-	-
XV	Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period)	(3,644.89)	(3,024.91)	(2,953.16)	9,847.41	(7,844.61)
XVI	Paid Up Equity share capital(Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63
XVII	Earnings per share (for continuing operation) :					
	(a) Basic	(12.21)	(9.94)	(9.88)	(32.81)	(26.19)
	(b) Diluted	(12.21)	(9.94)	(9.88)	(32.81)	(26.19)
XVIII	Earnings per share (for discontinued operation) :					
	(a) Basic	-	-	-	-	-
	(b) Diluted	-	-	-	-	-
XIX	Earnings per share (for discontinued & continuing operation) :					
	(a) Basic	(12.21)	(9.94)	(9.88)	(32.81)	(26.19)
	(b) Diluted	(12.21)	(9.94)	(9.88)	(32.81)	(26.19)



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is accredited by
JAS-ANZ MS0809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- The above results were reviewed by the audit committee at their meeting and thereafter approved by Board of Directors at the meeting held on 14-02-
- The statutory auditors of the company have carried out limited review of the aforesaid results.
- Additional information on standalone financial results are given below:

Particulars	Rs. In Lakh		Quarter Ended	Quarter Ended	Year to Date	Year to Date
	31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016	31-12-2016
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Total Income from operations	820.09	1,108.31	902.94	1,103.21	4,228.24	
Profit/Loss before tax	(3,092.31)	(2,906.18)	(3,097.74)	(3,693.96)	(8,419.95)	
Profit/Loss after tax	(2,470.77)	(2,330.95)	(2,663.23)	(3,943.33)	(7,143.85)	

- The Consolidated financial results for the quarter ended December 31, 2017 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017, the Company has for the first time adopted Ind AS with the transition date of April 1, 2016.
The Ind AS compliant corresponding figures for the previous quarter have not been subjected to review. However, the Company's management has exercised due diligence to ensure that such financial results provided a true and fair view of its affairs.
- Reconciliation of the net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:-

Description	Quarter ended	Year to Date
	31.12.2016	31.12.2016
	Rs. In lakh	Rs. In lakh
Net profit as per previous GAAP (Indian GAAP)	(2790.61)	(7436.32)
Provisions for receivable on Expected credit loss model	(37.48)	16.25
Fair valuation on account of Preference shares issued	(141.69)	(425.08)
Deferred tax Impact on above	11.57	(5.03)
Others	13.52	40.57
Net Profit as per Ind AS	(2944.69)	(7809.61)
Other comprehensive income (net of tax expenses)	(8.48)	(35.01)
Total comprehensive income	(2953.17)	(7844.62)

- At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- The previous period figures have been regrouped/rearranged wherever found necessary.
- The Consolidated financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Place: Indore
Date: 14th February 2018

Vinod Kumar Gupta
Managing Director
DIN 00039145



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register

Singhal Jain & Co.

Chartered Accountants

Consolidated Limited Review Report

Limited Review Report to

The Board of Directors of Parenteral Drugs (India) Limited

We have reviewed the accompanying statement of unaudited financial results of **Parenteral Drugs (India) Limited** and its subsidiaries for the quarter ended **31st December, 2017** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *"Review of Interim Financial Information performed by the Independent auditor of the entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The financial results and other financial information of the subsidiaries have not been subjected to review and have been presented based on the financial information compiled by the company.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. IND AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore (mp)

Date: 14/02/2018

For Singhal Jain & Co.



Chartered Accountants

CA Kamal Jain

(Partner) M. No. 406604

I.R.N.013995C

A-18, Inderpuri Colony, Behind Apex Mall, Lal Kothi, Jaipur
0141-4010787, 8233600787